This compound is a key intermediate in the synthesis of Itraconazole, a triazole-class antifungal agent used in human medicine to treat systemic and superficial fungal infections, such as aspergillosis, candidiasis, and dermatophytosis. The cis configuration ensures stereospecificity in the pharmaceutical manufacturing process, where it is reacted to form the dioxolane ring system integral to the drug's structure. With high purity levels (typically 97%), it is valued in the pharmaceutical industry for producing effective, broad-spectrum antifungals that inhibit ergosterol biosynthesis in fungal cells, disrupting membrane integrity. Its role supports the development of medications that provide targeted therapy with minimal impact on human cells.